Cell therapy is emerging as a cutting-edge precision treatment in ophthalmology and is gaining immense popularity worldwide among people affected by degenerative eye diseases. Traditional therapies ...

Expanding Product Portfolio: The iStent portfolio significantly boosted Glaukos' glaucoma franchise revenues in 2024. Additionally, the launch of iDose TR in the second quarter of 2024 is already ...

Corebridge Financial Inc. decreased its position in Glaukos Co. (NYSE:GKOS – Free Report) by 7.2% in the fourth quarter, ...

Congress Wealth Management LLC DE reduced its stake in Glaukos Co. (NYSE:GKOS – Free Report) by 22.4% in the 4th quarter, ...

to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject ...

With over 20 years of experience, he has pioneered minimally invasive glaucoma surgeries (MIGS), including Trabectome, iStent and canaloplasty, transforming patient care. His research also focuses ...